Tyrosine kinase inhibitors such as lapatinib, afatinib, and poziotinib have not yet been successfully developed for HER2-positive gastric cancer, especially as monotherapy, perhaps because their primary mechanism is to inhibit the HER2 pathway [12,13,80,81,82]. The gene discussed is ERBB2; the disease is gastric cancer.